Neurogene Inc.
Organization details
- Legal name
- Neurogene Inc.
- Former names
- Neoleukin Therapeutics, Inc. Aquinox Pharmaceuticals, Inc Aquinox Pharmaceuticals (USA) Inc
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Headquarters city
- New York
- Headquarters state / province
- New York
- Headquarters country
- Canada
- Fiscal year end
- December
- Ticker symbol
- NGNE
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001404644
- EIN
- 98-0542593
Board of directors
-
Christine Mikail Cvijic · Director · President and CFOSince 2026
-
Cory S. Freedland · DirectorSince 2023
-
Erin Lavelle · DirectorSince 2023
- Since 2023
- Since 2023
-
Keith Woods · DirectorSince 2023
-
Martin Babler · DirectorSince 2023
-
Rachel McMinn · Director · Chief Executive OfficerSince 2023
-
Robert Baffi · DirectorSince 2023
-
Robert Keith Woods · DirectorSince 2023
-
Rohan Palekar · DirectorSince 2023
-
Sarah B. Noonberg · DirectorSince 2023
-
Todd E. Simpson · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 3, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
94.6%
-
99.7%
Board connections
7 of this board's directors also sit on 23 other boards. 23 are in the same sector.
-
Prelude Therapeutics Incorporated Same sectorvia Felix Baker, Julian Baker and Martin Babler
-
TScan Therapeutics Inc. Same sectorvia Felix Baker, Julian Baker and Keith Woods
-
ACADIA Pharmaceuticals Inc. Same sectorvia Felix Baker and Julian Baker
-
BeOne Medicines Ltd. Same sectorvia Felix Baker and Julian Baker
-
Bicycle Therapeutics plc Same sectorvia Felix Baker and Julian Baker
-
DBV Technologies S.A. Same sectorvia Felix Baker and Julian Baker
-
Denali Therapeutics Inc. Same sectorvia Felix Baker and Julian Baker
-
Immunocore Holdings plc Same sectorvia Felix Baker and Julian Baker
-
Incyte Corp. Same sectorvia Felix Baker and Julian Baker
-
Kiniksa Pharmaceuticals International plc Same sectorvia Felix Baker and Julian Baker
-
Kodiak Sciences Inc Same sectorvia Felix Baker and Julian Baker
-
Kymera Therapeutics Inc. Same sectorvia Felix Baker and Julian Baker
-
Madrigal Pharmaceuticals Inc. Same sectorvia Felix Baker and Julian Baker
-
Replimune Group Inc. Same sectorvia Felix Baker and Julian Baker
-
vTv Therapeutics Inc. Same sectorvia Felix Baker and Julian Baker
-
Alumis Inc. Same sectorvia Martin Babler
-
Avalyn Pharma Inc. Same sectorvia Erin Lavelle
-
Jade Biosciences Inc. Same sectorvia Erin Lavelle
-
MapLight Therapeutics Inc. Same sectorvia Martin Babler
-
Protagonist Therapeutics Inc. Same sectorvia Sarah B. Noonberg
-
Rocket Pharmaceuticals Inc. Same sectorvia Keith Woods
-
X4 Pharmaceuticals Inc. Same sectorvia Keith Woods
-
Xencor Inc. Same sectorvia Todd E. Simpson
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $1,133,559
- 17 sales by 4 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 22, 2026 | Rachel McMinn Director, Officer (Chief Executive Officer) | Option exercise | +756 | $25.32 | $19,142 |
| Jul 7, 2026 | Christine Mikail Cvijic Director, Officer (President and CFO) | Open-market sale | −4,200 | $36.13 | $151,746 |
| Jul 6, 2026 | Christine Mikail Cvijic Director, Officer (President and CFO) | Open-market sale | −600 | $36.02 | $21,612 |
| Jul 2, 2026 | Christine Mikail Cvijic Director, Officer (President and CFO) | Open-market sale | −2,531 | $34.58 | $87,522 |
| Jul 2, 2026 | Christine Mikail Cvijic Director, Officer (President and CFO) | Open-market sale | −1,530 | $35.23 | $53,902 |
| Jul 1, 2026 | Christine Mikail Cvijic Director, Officer (President and CFO) | Open-market sale | −739 | $34.06 | $25,170 |
| May 6, 2026 | Christine Mikail Cvijic Director, Officer (President and CFO) | Open-market sale | −4,800 | $30.07 | $144,336 |
| May 6, 2026 | Christine Mikail Cvijic Director, Officer (President and CFO) | Open-market sale | −4,800 | $32.44 | $155,712 |
| Mar 26, 2026 | Cvijic Christine Mikail Officer (President and CFO) | Open-market sale | −2,558 | $21.62 | $55,304 |
| Mar 26, 2026 | Rachel McMinn Director, Officer (Chief Executive Officer) | Open-market sale | −3,352 | $22.07 | $73,979 |
| Mar 26, 2026 | Jordan Julie Officer (Chief Medical Officer) | Open-market sale | −828 | $21.89 | $18,125 |
| Mar 13, 2026 | Cobb Stuart Officer (Chief Scientific Officer) | Open-market sale | −3,991 | $20.41 | $81,456 |
| Mar 13, 2026 | Cvijic Christine Mikail Officer (President and CFO) | Open-market sale | −2,387 | $20.42 | $48,743 |
| Mar 13, 2026 | Cobb Stuart Officer (Chief Scientific Officer) | Open-market sale | −2,658 | $21.34 | $56,722 |
| Mar 13, 2026 | Cvijic Christine Mikail Officer (President and CFO) | Open-market sale | −1,395 | $21.25 | $29,644 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Neurogene Inc.
Who is the CEO of Neurogene Inc.?
Rachel McMinn has been Neurogene Inc.'s Chief Executive Officer since December 2023.
How many directors are on Neurogene Inc.'s board?
Neurogene Inc.'s board has 13 directors: Christine Mikail Cvijic, Cory S. Freedland, Erin Lavelle, Felix Baker, Julian Baker, Keith Woods, Martin Babler, Rachel McMinn, Robert Baffi, Robert Keith Woods and 3 others.
Are Neurogene Inc. insiders buying or selling shares?
Over the last 12 months, Neurogene Inc. insiders made no open-market purchases and sold $1.1 million of shares in 17 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="neurogene-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.